Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Centessa Pharmaceuticals (CNTA) Other Non-Current Assets (2021 - 2026)

Centessa Pharmaceuticals has reported Other Non-Current Assets over the past 5 years, most recently at $1.4 million for Q4 2025.

  • Quarterly Other Non-Current Assets fell 29.62% to $1.4 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $1.4 million through Dec 2025, down 29.62% year-over-year, with the annual reading at $1.4 million for FY2025, 29.62% down from the prior year.
  • Other Non-Current Assets was $1.4 million for Q4 2025 at Centessa Pharmaceuticals, down from $1.6 million in the prior quarter.
  • Over five years, Other Non-Current Assets peaked at $6.0 million in Q1 2023 and troughed at $619000.0 in Q1 2022.
  • The 5-year median for Other Non-Current Assets is $1.9 million (2025), against an average of $2.0 million.
  • Year-over-year, Other Non-Current Assets surged 875.77% in 2023 and then crashed 68.82% in 2024.
  • A 5-year view of Other Non-Current Assets shows it stood at $699000.0 in 2021, then soared by 168.96% to $1.9 million in 2022, then surged by 35.85% to $2.6 million in 2023, then decreased by 19.89% to $2.0 million in 2024, then fell by 29.62% to $1.4 million in 2025.
  • Per Business Quant, the three most recent readings for CNTA's Other Non-Current Assets are $1.4 million (Q4 2025), $1.6 million (Q3 2025), and $1.7 million (Q2 2025).